Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.
Resources
From our newsletters to the recordings of our webinars and everything in-between, use the filters (below) to find the content that's right for you.